Early market launch and peak sales through maximizing product value
First written in FY2017. 12 of 14 entries say "Advanced", first in FY2022-Q2. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「Last year, our internally discovered products ONO-4578 and ONO-2808 established proof of concept. To maximise the value of these drug candidates, we are developing development and clinical trial plans capable of achieving approvals as quickly as possible globally, in Japan, the United States and Europe, while making maximum use of Deciphera’s development functions in the United States and Europe and working steadily to conduct and execute international joint trials.」
ONO-4578 and ONO-2808 established proof of concept, and development plans and international joint trials aimed at obtaining global approvals moved forward. - FY2025AdvancedAnnual report
「For Ongentys, we will work to establish its usefulness early in the onset of wearing-off in patients with Parkinson’s disease and to increase recognition of wearing-off, while pursuing further growth with the aim of positioning it as the first Parkinson’s disease adjunctive therapy to be selected.」
The products targeted for value maximisation now explicitly include Ongentys in addition to Opdivo, and a specific target product position has been stated: the first adjunctive therapy to be selected. - FY2025-H1AdvancedAnnual report
「In May this year, approval was obtained in Japan for Braftovi capsules and Mektovi tablets, administered as a two-drug combination therapy, with the following indications: unresectable thyroid cancer with BRAF mutations that has progressed after cancer chemotherapy, and unresectable anaplastic thyroid cancer with BRAF mutations.」
Approval of Braftovi and Mektovi for thyroid cancer and other indications marked concrete progress toward maximising product value through additional indications. - FY2024AdvancedAnnual report
「In November last year, approval was obtained in Japan for Opdivo with malignant mesothelioma, excluding malignant pleural mesothelioma, as the indication. In February this year, approval was obtained in Japan for Opdivo with epithelial malignant skin tumours as the indication.」
Two additional indications for Opdivo were approved in Japan, marking concrete progress toward maximising product value. - FY2024-Q3AdvancedAnnual report
「Note 1: Approval was obtained in Japan for Opdivo for the indication of malignant mesothelioma, excluding malignant pleural mesothelioma.」
Approval was obtained in Japan for Opdivo for malignant mesothelioma, marking progress toward maximising product value through an additional indication. - FY2024-Q1AdvancedAnnual report
「※1: An application was submitted in Japan for Opdivo for the indication of epithelial skin malignancies. ※2: Applications were submitted in Japan for Braftovi capsules and Mektovi tablets for the indication of unresectable thyroid cancer with a BRAF mutation treated with the two-drug combination therapy.」
Applications for approval of additional indications were filed for multiple products, advancing the expansion of indications aimed at maximising product value. - FY2023AdvancedAnnual report
「Together with healthcare professionals, we will work to achieve the well-being of patients and their families and to ensure that new medicines become rapidly established as a result. To this end, we will pursue speedy and effective development, competitive marketing, and precise provision and collection of information. In development, we are currently conducting nearly 100 clinical trials, mainly in oncology, one of our key strategic fields.」
The policy of maximising product value has taken concrete form as a growth strategy combining patient and family well-being, approximately 100 clinical trials, marketing, and information provision and collection. - FY2023-Q2AdvancedAnnual report
「In May this year, approval was obtained in Japan for combination therapy with Yervoy and combination therapy with chemotherapy, with unresectable, advanced or recurrent oesophageal cancer as the indication. In July this year, approval was obtained in Taiwan for combination therapy with Yervoy and combination therapy with chemotherapy, with advanced or metastatic oesophageal squamous cell carcinoma as the indication.」
Approvals were obtained in Japan and Taiwan for Opdivo-related combination therapies for oesophageal cancer, advancing the maximisation of product value through additional indications. - FY2023-Q1AdvancedAnnual report
「Note 1: The company obtained approval in Japan and Taiwan for the combination of Opdivo and Yervoy and the combination of Opdivo and chemotherapy for the indication of unresectable advanced or recurrent esophageal cancer.」
The approvals in Japan and Taiwan for Opdivo combination therapies for oesophageal cancer represent concrete progress toward expanding indications and maximising product value. - FY2022AdvancedAnnual report
「In development, we are currently conducting nearly 100 clinical trials, mainly in oncology, one of our key strategic fields. Together with healthcare professionals, we will work to achieve the well-being of patients and their families, defined as a state of physical, mental and social well-being and satisfaction with life, and to ensure that new medicines become rapidly established as a result. To this end, we will pursue speedy and effective development, competitive marketing, and precise provision and collection of information.」
The policy of maximising product value has taken concrete form as a growth strategy combining patient and family well-being, approximately 100 clinical trials, marketing, and information provision. - FY2022-Q3AdvancedAnnual report
「Note 1: Approval was obtained in Japan for Opdivo with cancer of unknown primary origin as the indication.」
Approval was obtained in Japan for Opdivo for cancer of unknown primary origin, marking tangible progress toward maximising product value through an additional indication. - FY2022-Q2AdvancedAnnual report
「In August this year, approval was obtained in Japan for Forxiga tablets with chronic kidney disease as the indication, regardless of whether patients have type 2 diabetes, excluding patients with end-stage renal failure or those undergoing dialysis.」
Additional approval was obtained for Forxiga tablets for chronic kidney disease, advancing the expansion of indications aimed at maximising product value. - FY2018RestatedAnnual report
「To achieve sustainable growth, we will seek to maximise the value of products including Opdivo. Through active research and development, cross-functional collaboration across the Company and enhanced talent development capabilities, we will work not only to achieve early launches and obtain additional indications, and to reach peak sales as quickly as possible after launch, but also to maximise the potential of each product by promptly identifying changes in the environment at each stage of its life cycle and formulating strategies that can consistently maintain a competitive advantage.」
The plan to maximise product value, achieve early launches and add indications, and reach peak sales is reiterated. - FY2017First statedAnnual report
「To achieve sustainable growth, we will seek to maximise the value of products including Opdivo. Through active research and development, cross-functional collaboration across the Company and enhanced talent development capabilities, we will work not only to achieve early launches and obtain additional indications, and to reach peak sales as quickly as possible after launch, but also to maximise the potential of each product by promptly identifying changes in the environment at each stage of its life cycle and formulating strategies that can consistently maintain a competitive advantage.」
For the first time, the document systematically states the objectives of maximising the value of each product, achieving early launches, adding indications and reaching peak sales, while maintaining a competitive advantage at each stage of the life cycle.